Abstract
Background: Peri-implantitis is a pathological condition characterized by an inflammatory process involving soft and hard tissues surrounding dental implants. The management of peri-implant disease has several protocols, among which is the chemical method HYBENX®. The aim of this study is to demonstrate the efficacy of HYBENX® in the treatment of peri-implantitis and to compare HYBENX® with other chemical agents used in the surgical treatment of peri-implantitis. Methods: The present study included a population of ten subjects with severe peri-implantitis. The procedure used in the study involves the application of HYBENX® after open-flap debridement. Each patient has been followed for 12 months after a single application of the decontaminant agent. Clinical and radiographical parameters were recorded at baseline, 3 months, and 12 months after treatment completion. Results: At baseline, a mean pocket probing depth (PPD) of 7.3 ± 0.5 mm and a mean clinical attachment level (CAL) of 8.8 ± 0.8 mm was recorded. An average residual PPD of 4.2 ± 0.5 mm and a mean CAL of 5.2 ± 0.8 mm were observed after 1 year. Additionally, the average of bone gain was about 3.4 mm, with a mean marginal bone level (MBL) change from 5.8 mm (baseline) to 2.4 mm (12 months). In total, 90% of the treated implants reached the success rate after the 1-year follow-up. Only in one case out of ten treated implants was resolution of the disease not achieved. Conclusion: Clinical improvements highlight that the procedure of open-flap debridement (OFD) + HYBENX® may be considered an effective technique in the treatment of peri-implantitis. From the results obtained, it can be concluded that the use of HYBENX® in the surgical treatment of peri-implantitis is promising. Overall, this protocol demands further studies to better understand the role and potential benefits of HYBENX® in the treatment of peri-implantitis.
Highlights
During the last few years, several branches of dentistry have undergone major developments, most notably implantology
The aim of this study is to demonstrate the efficacy of HYBENX® to decontaminate the implant surface, in the case of mucositis and in the case of peri-implantitis and to stimulate bone regeneration of the affected area
The present study has shown that the use of HYBENX® seems to keep under control peri-implantitis and may reduce clinical and radiographic parameters
Summary
During the last few years, several branches of dentistry have undergone major developments, most notably implantology. There are two types of infection: the first affects only soft tissue (peri-implant mucositis) while the second results in the loss of supporting bone (peri-implantitis) [4]. Periimplant mucositis is usually reversible and is characterized by swelling and erythema of peri-implant mucosa, associated with bleeding on probing and probing depth (PD ≥ 4 mm) without bone loss. Peri-implantitis is a pathological condition concerning all peri-implant tissues, characterized by progressive bone loss around implants. The clinical signs of peri-implantitis are deep probing depth (≥6 mm), bleeding on probing (BOP+ ), radiographic evidence of bone loss and/or suppuration [5]. Peri-implantitis is a pathological condition characterized by an inflammatory process involving soft and hard tissues surrounding dental implants. The aim of this study is to demonstrate the efficacy of HYBENX® in the treatment of peri-implantitis and to compare HYBENX® with other chemical agents used in the surgical treatment of peri-implantitis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
